EA201190138A1 - Производные фуропиримидиндиона в качестве модуляторов trpa1 - Google Patents

Производные фуропиримидиндиона в качестве модуляторов trpa1

Info

Publication number
EA201190138A1
EA201190138A1 EA201190138A EA201190138A EA201190138A1 EA 201190138 A1 EA201190138 A1 EA 201190138A1 EA 201190138 A EA201190138 A EA 201190138A EA 201190138 A EA201190138 A EA 201190138A EA 201190138 A1 EA201190138 A1 EA 201190138A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
trpa1
furopyrimidindion
subfamily
acting
Prior art date
Application number
EA201190138A
Other languages
English (en)
Russian (ru)
Inventor
Сачин Сундарлал Чаудхари
Абрахам Томас
Ниша Параг Патил
Неелима Кхайраткар-Джоши
Индранил Мухопадхяй
Original Assignee
Гленмарк Фармасьютикалс, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42780205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201190138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Гленмарк Фармасьютикалс, С.А. filed Critical Гленмарк Фармасьютикалс, С.А.
Publication of EA201190138A1 publication Critical patent/EA201190138A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201190138A 2009-03-23 2010-03-22 Производные фуропиримидиндиона в качестве модуляторов trpa1 EA201190138A1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2213MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12
PCT/IB2010/000840 WO2010109329A1 (en) 2009-03-23 2010-03-22 Furopyrimidinedione derivatives as trpa1 modulators

Publications (1)

Publication Number Publication Date
EA201190138A1 true EA201190138A1 (ru) 2013-05-30

Family

ID=42780205

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201190138A EA201190138A1 (ru) 2009-03-23 2010-03-22 Производные фуропиримидиндиона в качестве модуляторов trpa1
EA201190139A EA022029B1 (ru) 2009-03-23 2010-03-23 Производные тиенопиримидиндиона в качестве модуляторов trpa1

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201190139A EA022029B1 (ru) 2009-03-23 2010-03-23 Производные тиенопиримидиндиона в качестве модуляторов trpa1

Country Status (22)

Country Link
US (4) US20120178766A1 (enExample)
EP (3) EP2411395B1 (enExample)
JP (2) JP2012521406A (enExample)
KR (2) KR20110128898A (enExample)
CN (3) CN102361874A (enExample)
AP (1) AP2948A (enExample)
AU (2) AU2010227225A1 (enExample)
BR (2) BRPI1013705A2 (enExample)
CA (2) CA2756535A1 (enExample)
DK (3) DK2411395T3 (enExample)
EA (2) EA201190138A1 (enExample)
ES (3) ES2424341T3 (enExample)
HU (1) HUE024538T2 (enExample)
IL (2) IL215177A (enExample)
MX (1) MX2011009822A (enExample)
PE (2) PE20120834A1 (enExample)
PL (3) PL2411395T3 (enExample)
PT (3) PT2411395E (enExample)
SG (4) SG174398A1 (enExample)
SI (3) SI2411395T1 (enExample)
WO (2) WO2010109329A1 (enExample)
ZA (2) ZA201107650B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
KR101591153B1 (ko) * 2010-12-20 2016-02-02 그렌마크 파머수티칼스 에스. 아. Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
RU2014100744A (ru) * 2011-06-13 2015-07-20 Гленмарк Фармасьютикалс С.А. Лечение респираторных нарушений с помощью trpa1 антагонистов
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
JP2014517062A (ja) * 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
US20140148423A1 (en) * 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
US20140364445A1 (en) * 2011-12-05 2014-12-11 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
AU2013273118B2 (en) * 2012-06-08 2015-11-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
PE20150598A1 (es) 2012-10-01 2015-05-20 Orion Corp Derivados de n-prop-2-inil carboxamida y su uso como antagonistas del receptor transitorio potencial de la subfamilia a, miembro 1
WO2014203210A1 (en) * 2013-06-20 2014-12-24 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
MX2016004741A (es) 2013-10-15 2016-07-26 Glenmark Pharmaceuticals Sa Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
EP3180337B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CN109310683A (zh) 2016-04-07 2019-02-05 杜克大学 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
JP7612682B2 (ja) 2019-10-15 2025-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なテトラゾール
IL301717B2 (en) * 2020-10-14 2026-05-01 Boehringer Ingelheim Int History of tetrazoles as TRPA1 inhibitors
KR20230087531A (ko) * 2020-10-14 2023-06-16 베링거 인겔하임 인터내셔날 게엠베하 Trpa1 억제제로서 테트라졸 유도체
WO2022179469A1 (zh) * 2021-02-23 2022-09-01 南京明德新药研发有限公司 噻吩并嘧啶二酮类化合物及其应用
JP7565457B2 (ja) 2021-04-14 2024-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＴＲＰＡ１阻害剤としての３Ｈ，４Ｈ－チエノ－［２，３－ｄ］ピリミジン－４－オン誘導体
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026139068A1 (zh) * 2024-12-26 2026-07-02 武汉朗来科技发展有限公司 作为trpa1抑制剂的化合物、其药物组合物和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6300334B1 (en) * 1998-08-28 2001-10-09 Astrazeneca Ab Thieno[2,3-d]pyrimidine-2,4-diones
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003288956A1 (en) * 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2005019188A1 (ja) 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
JPWO2006083005A1 (ja) 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
CA2617788A1 (en) * 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
DE602006014576D1 (de) * 2005-11-08 2010-07-08 Organon Nv Zur behandlung von mit trpv1 in zusammenhang stehenden erkrankungen geeignete 2-(benzimidazol-1yl)-n-(4-phenylthiazol-2-yl)acetamidderivate
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
EP1962855B1 (en) * 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2009002933A1 (en) * 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders
CN101711413B (zh) * 2007-06-25 2013-09-04 桑迪士克科技股份有限公司 具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
BRPI1009372A2 (pt) 2009-03-23 2016-05-31 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica e respectivos usos
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
AU2010308028A1 (en) 2009-10-15 2012-04-19 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102812022B (zh) 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
CN102666507B (zh) 2010-07-13 2014-09-17 诺华股份有限公司 噁嗪衍生物及其在治疗神经病症中的用途

Also Published As

Publication number Publication date
MX2011009822A (es) 2012-01-25
SI2411396T1 (sl) 2013-07-31
KR101524337B1 (ko) 2015-05-29
US20120295924A1 (en) 2012-11-22
SG184769A1 (en) 2012-10-30
CA2756535A1 (en) 2010-09-30
KR20110128898A (ko) 2011-11-30
IL215175A (en) 2014-01-30
HK1166073A1 (en) 2012-10-19
IL215177A0 (en) 2011-12-29
PT2411395E (pt) 2013-06-06
US8507503B2 (en) 2013-08-13
US20150150876A1 (en) 2015-06-04
PL2411396T3 (pl) 2013-10-31
CN102361877A (zh) 2012-02-22
EP2411396B1 (en) 2013-05-29
ES2424341T3 (es) 2013-10-01
BRPI1009381B1 (pt) 2020-04-14
DK2634191T3 (en) 2015-03-23
WO2010109334A3 (en) 2010-11-25
IL215175A0 (en) 2011-12-29
IL215177A (en) 2014-01-30
DK2411396T3 (da) 2013-08-05
AU2010227230A1 (en) 2011-09-22
EP2411395A1 (en) 2012-02-01
SG174398A1 (en) 2011-10-28
EP2634191A1 (en) 2013-09-04
CN103755720A (zh) 2014-04-30
PE20120834A1 (es) 2012-07-25
US20130289054A1 (en) 2013-10-31
BRPI1009381A2 (pt) 2016-06-21
CN102361877B (zh) 2014-05-07
PL2634191T3 (pl) 2015-06-30
EP2411395B1 (en) 2013-05-29
HUE024538T2 (hu) 2016-01-28
JP2012521406A (ja) 2012-09-13
SG184767A1 (en) 2012-10-30
KR20120004422A (ko) 2012-01-12
SG174404A1 (en) 2011-10-28
ES2424342T3 (es) 2013-10-01
AU2010227225A2 (en) 2011-10-06
SI2411395T1 (sl) 2013-07-31
BRPI1013705A2 (pt) 2016-04-05
PL2411395T3 (pl) 2013-10-31
US20120178766A1 (en) 2012-07-12
EA022029B1 (ru) 2015-10-30
US9474758B2 (en) 2016-10-25
JP5612070B2 (ja) 2014-10-22
EP2634191B1 (en) 2014-12-24
DK2411395T3 (da) 2013-08-05
CA2756536C (en) 2015-10-06
PT2634191E (pt) 2015-03-04
PE20120775A1 (es) 2012-06-27
ES2532386T3 (es) 2015-03-26
HK1166074A1 (en) 2012-10-19
WO2010109329A1 (en) 2010-09-30
JP2012521407A (ja) 2012-09-13
CN103755720B (zh) 2016-07-06
AU2010227230A2 (en) 2011-10-27
BRPI1009381B8 (pt) 2021-05-25
PT2411396E (pt) 2013-06-06
SI2634191T1 (sl) 2015-04-30
AU2010227230B2 (en) 2015-11-26
AP2011005889A0 (en) 2011-10-31
WO2010109334A2 (en) 2010-09-30
AP2948A (en) 2014-07-31
ZA201107649B (en) 2012-07-25
US8987278B2 (en) 2015-03-24
EP2411396A2 (en) 2012-02-01
CA2756536A1 (en) 2010-09-30
EA201190139A1 (ru) 2012-03-30
CN102361874A (zh) 2012-02-22
ZA201107650B (en) 2012-07-25
AU2010227225A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
EA201190139A1 (ru) Производные тиенопиримидиндиона в качестве модуляторов trpa1
EA201190143A1 (ru) Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
EA201190191A1 (ru) Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1
WO2009118596A3 (en) Phthalimide derivatives as trpa1 modulators
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
ATE530524T1 (de) Substituierte sulfonamid-derivate
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
WO2010010435A3 (en) Fused oxazole and thiazole derivatives as trpms modulators
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EA201190086A1 (ru) Сочлененные производные имидазола в качестве антагониста trpv3
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
UA104861C2 (uk) Похідні хроману як модулятори trpv3
EA201390055A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОПИРАЗОЛО[3,4-b]АЗЕПИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРОВ